Stocklytics Platform
Asset logo for symbol CALT
Calliditas Therapeutics AB
CALT45
$40.000.00%$0.00
Asset logo for symbol CALT
CALT45

$40.00

0.00%

Performance History

Chart placeholder
Key Stats
Open$40.00
Prev. Close$40.00
EPS-1.76
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range40.00
40.00
52 Week Range15.25
43.00
Ratios
Revenue-
EPS-1.76

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Calliditas Therapeutics AB (CALT)

Calliditas Therapeutics AB (CALT) is a biopharmaceutical company specializing in developing and commercializing innovative treatments for patients with rare and severe kidney disorders. The company's primary focus is on the development of Nefecon, a drug candidate designed to address the unmet medical needs of patients with IgA nephropathy, a chronic autoimmune kidney disease. Nefecon has shown promising results in clinical trials, and Calliditas Therapeutics is working towards obtaining regulatory approval for its commercialization.
In terms of stock price history, Calliditas Therapeutics has seen significant growth since its initial public offering (IPO) in 2018. The stock has steadily increased in value, reflecting the market's confidence in the company's potential for success. Investors have been attracted to Calliditas Therapeutics due to its strong pipeline of innovative treatments and the potential for significant returns on investment.
Sector
Healthcare
Industry
Biotechnology
CEO
Headquarters
Stockholm
Employees
169
Exchange
NASDAQ
add Calliditas Therapeutics AB  to watchlist

Keep an eye on Calliditas Therapeutics AB

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Calliditas Therapeutics AB 's (CALT) price per share?

The current price per share for Calliditas Therapeutics AB (CALT) is $40. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Calliditas Therapeutics AB (CALT)?

For Calliditas Therapeutics AB (CALT), the 52-week high is $43, which is 7.5% from the current price. The 52-week low is $15.25, the current price is 162.3% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Calliditas Therapeutics AB (CALT) a growth stock?

Calliditas Therapeutics AB (CALT) has shown an average price growth of -3.55% over the past three years. It has received a score of 87 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Calliditas Therapeutics AB as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Calliditas Therapeutics AB (CALT) stock price performance year to date (YTD)?

As of the latest data, Calliditas Therapeutics AB (CALT) has a year-to-date price change of 60.01%. Over the last three months, the change has been 1.94%. Over the past six months, the figure is 90.3%.
help

Is Calliditas Therapeutics AB (CALT) a profitable company?

Calliditas Therapeutics AB (CALT) has a net income of -$466.18M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 93.62% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -5.63% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 50.32%, providing insight into the company's sales performance and growth. The gross profit is $1.13B. Operating income is noted at -$384.4M. Furthermore, the EBITDA is $342.3M.
help

What is the market capitalization of Calliditas Therapeutics AB (CALT)?

Calliditas Therapeutics AB (CALT) has a market capitalization of $723.12M. The average daily trading volume is 2.5K, indicating the stock's liquidity and investor engagement.

News

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level